MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercises
of stock options
$2,279K
Proceeds from issuance of
common stock under...
$196K
Net cash provided by
financing activities
$2,441K
Canceled cashflow
$34K
Net increase
(decrease) in cash, cash...
-$224,314K
Canceled cashflow
$2,441K
Stock-based compensation
expense
$10,332K
Accrued expenses and
other current...
$4,014K
Non-cash lease expense
$561K
Depreciation and
amortization expense
$188K
Maturities of short-term
investments
$292,563K
Payments of initial
public offering costs
$34K
Net cash used in
operating activities
-$133,275K
Net cash used in
investing activities
-$93,480K
Canceled cashflow
$15,095K
Canceled cashflow
$292,563K
Net loss
-$143,443K
Purchases of short-term
investments
$385,878K
Prepaid expenses and
other assets
$1,524K
Net amortization of
premiums and accretion of...
$1,502K
Accounts payable
-$1,281K
Operating lease
liabilities
-$565K
Accounts receivable
$55K
Purchases of equipment
$165K
Back
Back
Cash Flow
source: myfinsight.com
Upstream Bio, Inc. (UPB)
Upstream Bio, Inc. (UPB)